Life quality gains with Enjaymo sustained for 2.5 years

Long-term treatment with Enjaymo (sutimlimab-jome) led to sustained improvements in life quality and reductions in fatigue for people with cold agglutinin disease (CAD), according to 2.5 years of data from the Phase 3 CARDINAL clinical trial. “[Enjaymo] provides sustained and durable treatment benefits in chronic CAD, including a…